Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Fineline Cube Jan 10, 2026
Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026
Company Deals

Viva Biotech and CMS Forge AI-Powered Drug Development Alliance

Fineline Cube Jan 8, 2026
Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Fineline Cube Jan 10, 2026
Company Drug

Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity

Fineline Cube Jan 10, 2026
Company Deals

XtalPi and Chia Tai Tianqing Achieve Phase II Milestone in Cancer Drug Development

Fineline Cube Mar 13, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has partnered with China’s Chia Tai Tianqing to...

Company Deals

Overland Pharmaceuticals Partners with GoBroad Healthcare to Strengthen Cell Therapy Research

Fineline Cube Mar 13, 2023

China-based firm Overland Pharmaceuticals has entered into a strategic partnership with GoBroad Healthcare Group to...

Company Drug

Haihe Pharmaceutical Initiates Global Phase I Clinical Study for BET-BD2 Inhibitor HH3806

Fineline Cube Mar 13, 2023

Shanghai Haihe Pharmaceutical Co., Ltd has announced the first patient dosing of a global multi-center...

Company Drug

CanSino Biologics Initiates Phase Ib Study for Innovative Protein-Based Pneumococcal Vaccine

Fineline Cube Mar 13, 2023

China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...

Company Deals

Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development

Fineline Cube Mar 13, 2023

China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100...

Company Deals

Livzon Pharmaceutical Secures Exclusive Rights to Onconic’s GERD Treatment Zastaprazan

Fineline Cube Mar 13, 2023

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with South Korean...

Company Drug

CStone’s Ayvakit Shows Significant Improvements in ISM at AAAAI Meeting

Fineline Cube Mar 13, 2023

China-based CStone Pharmaceuticals (HKG: 2616) announced that its US partner, Blueprint Medicines, published detailed data...

Company Medical Device

Lifetech’s IBS Angel Stent System Gains EU CE MDR Certification

Fineline Cube Mar 10, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...

Company Deals

Olipharma Secures Funding for Manufacturing Expansion in Pre-Series A+ Round

Fineline Cube Mar 10, 2023

Olipharma, a Contract Development and Manufacturing Organization (CDMO) specializing in small nucleic acid drugs and...

Company Drug

Inventiva and Chia Tai Tianqing’s Lanifibranor Advances with CDE Filing

Fineline Cube Mar 10, 2023

France-based Inventiva S.A. and China’s Chia Tai Tianqing have successfully filed a clinical trial application...

Company Drug

Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody

Fineline Cube Mar 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...

Deals Drug

AusperBio and Asymchem Form Strategic Partnership for Drug Development

Fineline Cube Mar 10, 2023

China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...

Policy / Regulatory

NHSA’s 2022 Healthcare Security Bulletin Reveals Break-Even Performance

Fineline Cube Mar 10, 2023

The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...

Company Drug

Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008

Fineline Cube Mar 10, 2023

China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...

Company Drug

Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma

Fineline Cube Mar 10, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...

Company Deals

HuiLiao Biomedical Raises RMB 100 Million in Pre-Series A Round for mRNA Development

Fineline Cube Mar 10, 2023

China-based nucleic acid drug specialist Suzhou HuiLiao Biomedical Technology Co., Ltd has reportedly raised over...

Company Drug

InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China

Fineline Cube Mar 10, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...

Company Deals

Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Therapies

Fineline Cube Mar 10, 2023

China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million)...

Company Deals

Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development

Fineline Cube Mar 10, 2023

Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions”...

Company Medical Device

Lifetech Scientific’s IBS Angel Stent Receives CE MDR Certification in EU

Fineline Cube Mar 10, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...

Posts pagination

1 … 492 493 494 … 606

Recent updates

  • Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy
  • InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
  • MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal
  • Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity
  • Lilly’s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Company Drug

Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.